EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Does bilateral mastectomy affect clinical outcomes in BRCA1/2 mutation carriers with primary breast cancer? A systematic review and meta-analysis

Pedro Henrique de Souza Wagner, Gustavo Tadeu Freitas Uchôa Matheus, Hideki Zimermann Kamitani, Pedro Lucas Azevedo de Carvalho, Francisco Cezar Aquino de Moraes

Familial Cancer · 2026

DOI: 10.1007/s10689-026-00535-6 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Familial Cancer, 2026. Verfasst von Pedro Henrique de Souza Wagner und 4 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of Santa Catarina, Florianópolis, Santa Catarina, 88035-972, Brazil. pedrowagner8566@gmail.com. Hauptthemen laut MEDLINE: BRCA1 Protein, BRCA2 Protein, Breast Neoplasms, Mastectomy. Die Arbeit nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: BRCA1/2-carriers—who account for 5–10% of breast cancer (BC) cases—face markedly elevated lifetime risks of BC. Among those diagnosed with primary breast cancer (PBC), these carriers confront a cumulative contralateral breast cancer (CBC) risk of 40% within 10 years—alongside poorer overall survival (OS) and breast cancer–specific survival (BCSS). Whether contralateral risk-reducing mastectomy (CRRM) can improve OS, BCSS, and reduce CBC risk in this high-risk group remains unresolved. PATIENTS AND METHODS: We conducted a systematic review and meta-analysis of cohort studies (PROSPERO:CRD420251024265). PubMed, Embase, Cochrane Library were searched through June 2025. Studies enrolled BRCA1/2-carriers with PBC, compared CRRM versus Non-CRRM, and reported OS, BCSS, or CBC risk. We pooled hazard ratio (HR) and risk ratio (RR) for these outcomes. Heterogeneity was quantified by I2. RESULTS: This meta‐analysis included nine cohort studies, encompassing BRCA1/2-carriers with PBC. In the OS analysis, including 3138 patients in the CRRM group versus 2,592 in the Non-CRRM group, CRRM presented a substantial survival benefit (HR 0.638; P < 0.001). BCSS (567 CRRM and 623 Non-CRRM patients), likewise demonstrated an advantage for the CRRM group (HR 0.601; P = 0.005). CBC risk, evaluated in 637 CRRM and 976 Non-CRRM patients, was reduced by 91% (RR 0.090; P < 0.001), reflecting an absolute risk reduction of 188 CBC events per 1000. CONCLUSION: CRRM confers substantial oncologic benefits, improving OS and BCSS and reducing CBC risk in BRCA1/2 carriers with PBC, and should be considered for this high-risk population, informing guideline recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsMastectomyProphylactic MastectomyFemaleHumansGenes, BRCA1Genes, BRCA2HeterozygoteMutation

Stichwörter der Autor:innen

BRCA1/2Breast cancer-specific survivalContralateral breast cancerContralateral risk-reducing mastectomyOverall survivalPrimary breast cancer

Substanzen

BRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human

Autor:innen und Institutionen

  • Federal University of Santa Catarina, Florianópolis, Santa Catarina, 88035-972, Brazil. pedrowagner8566@gmail.com.
  • Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, 38025-440, Brazil.
  • Federal University of São Francisco Valley, Paulo Afonso, Bahia, 48605-560, Brazil.
  • Federal University of Amazonas, Manaus, Amazonas, 69060-094, Brazil.
  • Federal University of Pará, Belém, Pará, 66073-005, Brazil.

Zitieren

APA

de Souza Wagner, P. H., Freitas Uchôa Matheus, G. T., Zimermann Kamitani, H., Azevedo de Carvalho, P. L., & de Moraes, F. C. A. (2026). Does bilateral mastectomy affect clinical outcomes in BRCA1/2 mutation carriers with primary breast cancer? A systematic review and meta-analysis. Familial Cancer. https://doi.org/10.1007/s10689-026-00535-6

Vancouver

de Souza Wagner PH, Freitas Uchôa Matheus GT, Zimermann Kamitani H, Azevedo de Carvalho PL, de Moraes FCA. Does bilateral mastectomy affect clinical outcomes in BRCA1/2 mutation carriers with primary breast cancer? A systematic review and meta-analysis. Familial Cancer. 2026. doi:10.1007/s10689-026-00535-6

BibTeX
@article{deSouzaWagner2026,
  author = {de Souza Wagner, Pedro Henrique and Freitas Uchôa Matheus, Gustavo Tadeu and Zimermann Kamitani, Hideki and Azevedo de Carvalho, Pedro Lucas and de Moraes, Francisco Cezar Aquino},
  title = {Does bilateral mastectomy affect clinical outcomes in BRCA1/2 mutation carriers with primary breast cancer? A systematic review and meta-analysis},
  journal = {Familial Cancer},
  year = {2026},
  doi = {10.1007/s10689-026-00535-6}
}
Kostenlos starten →